Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David H Johnson

Showing results (21-30 of 220) with videos related to

Pageof 22
Sort By:
Seminars in Oncology|March 15, 2002
Seminars in oncology. IntroductionPaul A Bunn, David H Johnson
Cancer Chemotherapy and Biological Response Modifiers|April 22, 2003
Novel therapies for the treatment of non-small cell lung cancerDavid H Johnson, Joan H Schiller
The American Journal of Medicine|August 3, 2016
The Department of Medicine in 2030: A Look AheadDavid L Coleman, David H Johnson
JAMA Oncology|July 9, 2017
Conflict of Interest, Conflicting Interests, and Effective Collaboration Between Academia and Industry on Preclinical and Clinical Cancer ResearchMace L Rothenburg, David H Johnson
BMJ Case Reports|March 30, 2018
Pemberton's sign in SVC syndrome from metastatic renal cell carcinomaNeil Keshvani, Christina Yek, David H Johnson
Expert Opinion on Therapeutic Targets|May 5, 2009
Targeting the eicosanoid pathway in non-small-cell lung cancerLeora Horn, Michael Backlund, David H Johnson
JAMA|September 13, 2017
Antiphospholipid AntibodiesArjun Gupta, David H Johnson, Srikanth Nagalla
Journal of the National Cancer Institute|August 7, 2003
An advance in small-cell lung cancer treatment--more or lessJanessa Laskin, Alan Sandler, David H Johnson
JAMA Internal Medicine|July 11, 2018
Devolution and Devaluation of Fecal Leukocyte Testing: A 100-Year HistoryArjun Gupta, David H Johnson, Deepak Agrawal
The Journal of Supportive Oncology|February 3, 2007
Role of chemotherapy for palliation in the lung cancer patientShannon Stinnett, Laura Williams, David H Johnson
Pageof 22

Showing results (21-30 of 220) with videos related to

Sort By:
Pageof 22
Seminars in Oncology|March 15, 2002
Seminars in oncology. IntroductionPaul A Bunn, David H Johnson
Cancer Chemotherapy and Biological Response Modifiers|April 22, 2003
Novel therapies for the treatment of non-small cell lung cancerDavid H Johnson, Joan H Schiller
The American Journal of Medicine|August 3, 2016
The Department of Medicine in 2030: A Look AheadDavid L Coleman, David H Johnson
JAMA Oncology|July 9, 2017
Conflict of Interest, Conflicting Interests, and Effective Collaboration Between Academia and Industry on Preclinical and Clinical Cancer ResearchMace L Rothenburg, David H Johnson
BMJ Case Reports|March 30, 2018
Pemberton's sign in SVC syndrome from metastatic renal cell carcinomaNeil Keshvani, Christina Yek, David H Johnson
Expert Opinion on Therapeutic Targets|May 5, 2009
Targeting the eicosanoid pathway in non-small-cell lung cancerLeora Horn, Michael Backlund, David H Johnson
JAMA|September 13, 2017
Antiphospholipid AntibodiesArjun Gupta, David H Johnson, Srikanth Nagalla
Journal of the National Cancer Institute|August 7, 2003
An advance in small-cell lung cancer treatment--more or lessJanessa Laskin, Alan Sandler, David H Johnson
JAMA Internal Medicine|July 11, 2018
Devolution and Devaluation of Fecal Leukocyte Testing: A 100-Year HistoryArjun Gupta, David H Johnson, Deepak Agrawal
The Journal of Supportive Oncology|February 3, 2007
Role of chemotherapy for palliation in the lung cancer patientShannon Stinnett, Laura Williams, David H Johnson
Pageof 22